RareCyte
PrivateLast Round
Grant
Aug 21, 2025
Total Funding Raised
$52.5M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
RareCyte is a biotechnology company that provides end-to-end platforms for the multiplexed analysis of cells and tissue in research and clinical diagnostics.
Sector
Healthcare & Life Sciences
Verticals
Biotech Equipment, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting, Hardware Sales, Hardware + Subscription, Government Contracts
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
RareCyte Comps
Public and private peers based on sector, stage, and business model.
| Company | Status | Est. Valuation | Rev Multiple |
|---|---|---|---|
| OpenAI | Private | $86.0B | ~40x |
| Cohere | Private | $5.0B | -- |
| Competitor 1 | Public | $XX.XB | XXx |
| Competitor 2 | Public | $XX.XB | XXx |
RareCyte Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Aug 21, 2025 | ||||
| VC Round | Jun 27, 2024 | ||||
| VC Round | Sep 9, 2021 | ||||
| Series F | Dec 19, 2019 | ||||
| Series D | Aug 29, 2017 | ||||
VC Round | Aug 22, 2012 |
Key People
Founding team and executive leadership
RareCyte Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Arboretum Ventures | VC Round |
| F-Prime Capital | VC Round |
| The Forest Road Company | VC Round |
| Gates Family Foundation | Grant |
| 5AM Ventures | Series F, VC Round, Series D |
| Logos Capital | VC Round |
| Bill & Melinda Gates Foundation | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 21, 2026
Launched Orion HT and Orion LE systems, expanding spatial proteomics portfolio.
- Apr 21, 2026
Neil Kennedy appointed as the new President.
RareCyte Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about RareCyte's valuation, stock price, and market status.